Tags

Type your tag names separated by a space and hit enter

Ceftaroline fosamil: drug profile and clinical data.
Future Microbiol. 2011 Jan; 6(1):9-18.FM

Abstract

Several studies have shown that the rates of resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), hetero-VISA, and penicillin-resistant Streptococcus pneumoniae have witnessed a substantial global increase. Ceftaroline fosamil is the prodrug form of ceftaroline, a new cephalosporin active against resistant Gram-positive pathogens and common Gram-negative organisms that do not produce extended-spectrum-β-lactamases and do not express AmpC. Ceftaroline fosamil was found to be effective and well-tolerated for the treatment of complicated skin and skin-structure infections and community-acquired bacterial pneumonia compared with standard therapy. The drug has recently been granted US FDA approval for both indications.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kanafani ZA
American University of Beirut Medical Center, PO Box 11-0236/11D, Riad El Solh 1107 2020, Beirut, Lebanon. zk10@aub.edu.lb

MeSH

AnimalsAnti-Bacterial AgentsCephalosporinsClinical Trials as TopicCommunity-Acquired InfectionsDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaHumansMiceMicrobial Sensitivity TestsPneumonia, BacterialRabbitsSkin Diseases, Bacterialbeta-Lactamases

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21162631

Citation

Kanafani, Zeina A.. "Ceftaroline Fosamil: Drug Profile and Clinical Data." Future Microbiology, vol. 6, no. 1, 2011, pp. 9-18.
Kanafani ZA. Ceftaroline fosamil: drug profile and clinical data. Future Microbiol. 2011;6(1):9-18.
Kanafani, Z. A. (2011). Ceftaroline fosamil: drug profile and clinical data. Future Microbiology, 6(1), 9-18. https://doi.org/10.2217/fmb.10.132
Kanafani ZA. Ceftaroline Fosamil: Drug Profile and Clinical Data. Future Microbiol. 2011;6(1):9-18. PubMed PMID: 21162631.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline fosamil: drug profile and clinical data. A1 - Kanafani,Zeina A, PY - 2010/12/18/entrez PY - 2010/12/18/pubmed PY - 2011/6/8/medline SP - 9 EP - 18 JF - Future microbiology JO - Future Microbiol VL - 6 IS - 1 N2 - Several studies have shown that the rates of resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), hetero-VISA, and penicillin-resistant Streptococcus pneumoniae have witnessed a substantial global increase. Ceftaroline fosamil is the prodrug form of ceftaroline, a new cephalosporin active against resistant Gram-positive pathogens and common Gram-negative organisms that do not produce extended-spectrum-β-lactamases and do not express AmpC. Ceftaroline fosamil was found to be effective and well-tolerated for the treatment of complicated skin and skin-structure infections and community-acquired bacterial pneumonia compared with standard therapy. The drug has recently been granted US FDA approval for both indications. SN - 1746-0921 UR - https://www.unboundmedicine.com/medline/citation/21162631/Ceftaroline_fosamil:_drug_profile_and_clinical_data_ DB - PRIME DP - Unbound Medicine ER -